日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial

劳拉替尼治疗未接受过酪氨酸激酶抑制剂治疗的晚期 ROS1 阳性非小细胞肺癌:一项 II 期非随机临床试验

Ahn, Beung Chul; Kim, Yu Jung; Lee, Youngjoo; Suh, Koung Jin; Kim, Se Hyun; Kim, Dong-Wan; Kim, Tae Min; Lee, Ki Hyeong; Han, Ji-Youn

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥洛莫拉西布(一种新一代 KRAS G12C 抑制剂)在 KRAS G12C 突变型晚期实体瘤中的泛肿瘤活性:一项首次人体研究

Murciano-Goroff, Yonina R; Hollebecque, Antoine; Heist, Rebecca S; Cassier, Philippe A; Han, Ji-Youn; Kim, So Yeon; Sabari, Joshua K; Tosi, Diego; Sacher, Adrian; Burns, Timothy F; Shimizu, Toshio; Reddy Ammakkanavar, Natraj; Spira, Alexander; Gomez-Roca, Carlos; Patnaik, Amita; Cosman, Rasha; Bodor, J Nicholas; Nagasaka, Misako; You, Arthur Xintian; McNeely, Samuel C; Peter, Raimund; Fink, Aaron; Chen, Aaron; Oxnard, Geoffrey R; Willard, Melinda D; Kuboki, Yasutoshi; Koyama, Takafumi

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC

JIN-A02 是一种突变选择性第四代 EGFR 抑制剂,可克服 C797S 介导的耐药性,并在非小细胞肺癌中显示出颅内活性。

Lee, Eun Ji; Ko, Ji Ae; Kim, Min-Je; Cho, Jae Seok; Han, Ji-Youn; Kim, Sang We; Lee, Ki Hyeong; Shim, Byoung Yong; Sun, Jong-Mu; Nagasaka, Misako; Park, Sewon; Oh, Seung Yeon; Hong, Min Hee; Lee, Jii Bum; Jo, Anna; Seah, Ethan; Cho, Byoung Chul; Lim, Sun Min

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones.

对难治性肺癌进行纵向药物基因组学分析,以确定表皮生长因子受体酪氨酸激酶抑制剂耐药亚克隆的治疗候选药物

Yu Namhee, Hwang Mihwa, Ahn Beung Chul, Lee Youngjoo, Hong Sehwa, Sim Hanna, Song Bo Ram, Kim Sunshin, Park Charny, Han Ji-Youn

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

VEGF信号复杂性导致EGFR酪氨酸激酶抑制剂耐药的非小细胞肺癌对阿特珠单抗、贝伐珠单抗、卡铂和紫杉醇产生耐药性

Hong, Sehwa; Yu, Namhee; Cho, Ju Young; Lee, Geon Kook; Ahn, Beung-Chul; Lee, Youngjoo; Sim, Hanna; Song, Bo Ram; Hwang, Mihwa; Kim, Sunshin; Kim, Jung-Hyun; Park, Charny; Han, Ji-Youn

Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer

既往接受过治疗的小细胞肺癌患者接受 Tarlatamab 治疗的 II 期 DeLLphi-301 研究中亚洲亚组分析

Ahn, Myung-Ju; Cho, Byoung Chul; Ohashi, Kadoaki; Izumi, Hiroki; Lee, Jong-Seok; Han, Ji-Youn; Chiang, Chi-Lu; Huang, Shuang; Hamidi, Ali; Mukherjee, Sujoy; Xu, Krista Lin; Akamatsu, Hiraoki

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial

ALTA-1L试验中一线布加替尼治疗后的真实世界治疗模式和后续治疗效果

Ahn, Myung-Ju; Delmonte, Angelo; Ghosh, Sharmistha; Hochmair, Maximilian; Yang, Tsung-Ying; Yang, James Chih-Hsin; Han, Ji-Youn; Hansen, Karin Holmskov; Wu, Yanyu; Wan, Yin; Lin, Huamao Mark; Kretz, Julian; Hupf, Bradley; Kurec, Ahmet Melih; Churchill, Eric N; Fram, Robert J; Cabasag, Citadel Jungco; Goriya, Vishal; Zhao, Yuzhe; Campelo, Maria Rosario García

Neutrophil extracellular traposis in cancer patients with acute ischemic stroke

癌症合并急性缺血性卒中患者的中性粒细胞胞外陷阱形成

Hyun, Jae-Won; Payumo, Rosah May Palermo; Chung, Jieun; Kang, You-Ri; Kim, Su-Hyun; Kim, Ho Jin; Han, Ji-Youn; Park, Sang-Yoon

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

在难治性表皮生长因子受体突变型非小细胞肺癌中,皮下注射与静脉注射阿米伐他单抗联合拉泽替尼的疗效比较:来自 III 期 PALOMA-3 研究的主要结果

Leighl, Natasha B; Akamatsu, Hiroaki; Lim, Sun Min; Cheng, Ying; Minchom, Anna R; Marmarelis, Melina E; Sanborn, Rachel E; Chih-Hsin Yang, James; Liu, Baogang; John, Thomas; Massutí, Bartomeu; Spira, Alexander I; Lee, Se-Hoon; Wang, Jialei; Li, Juan; Liu, Caigang; Novello, Silvia; Kondo, Masashi; Tamiya, Motohiro; Korbenfeld, Ernesto; Moskovitz, Mor; Han, Ji-Youn; Alexander, Mariam; Joshi, Rohit; Felip, Enriqueta; Voon, Pei Jye; Danchaivijitr, Pongwut; Hsu, Ping-Chih; Silva Melo Cruz, Felipe José; Wehler, Thomas; Greillier, Laurent; Teixeira, Encarnação; Nguyen, Danny; Sabari, Joshua K; Qin, Angel; Kowalski, Dariusz; Şendur, Mehmet Ali Nahit; Xie, John; Ghosh, Debopriya; Alhadab, Ali; Haddish-Berhane, Nahor; Clemens, Pamela L; Lorenzini, Patricia; Verheijen, Remy B; Gamil, Mohamed; Bauml, Joshua M; Baig, Mahadi; Passaro, Antonio

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

在 II 期 LUMINOSITY 试验中,Telisotuzumab Vedotin 单药治疗既往接受过治疗的 c-Met 蛋白过表达的晚期非鳞状 EGFR 野生型非小细胞肺癌患者

Camidge, D Ross; Bar, Jair; Horinouchi, Hidehito; Goldman, Jonathan; Moiseenko, Fedor; Filippova, Elena; Cicin, Irfan; Ciuleanu, Tudor; Daaboul, Nathalie; Liu, Chunling; Bradbury, Penelope; Moskovitz, Mor; Katgi, Nuran; Tomasini, Pascale; Zer, Alona; Girard, Nicolas; Cuppens, Kristof; Han, Ji-Youn; Wu, Shang-Yin; Baijal, Shobhit; Mansfield, Aaron S; Kuo, Chih-Hsi; Nishino, Kazumi; Lee, Se-Hoon; Planchard, David; Baik, Christina; Li, Martha; Ansell, Peter; Xia, Summer; Bolotin, Ellen; Looman, Jim; Ratajczak, Christine; Lu, Shun